BioPharma Dive January 25, 2022
The Series B round significantly swells Metagenomi’s funding, just three months after the biotech partnered with Moderna.
Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on its early research exploring new ways to edit genes.
The Series B round is sizable for a company at Metagenomi’s stage and comes as biotech startups, accustomed to record levels of investment in recent years, face a tougher market environment. Shares of publicly traded drugmakers have fallen significantly, adding new risk to what’s typically been a fast track toward an initial stock offering for young biotechs.
Still, Simon Harnest, Metagenomi’s chief investment officer, said the company had significant interest from...
Today's Sponsors
Today's Sponsor